Blood test may predict nausea from breast cancer treatment
NCT ID NCT07465172
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 150 breast cancer patients starting T-DXd, a drug that often causes nausea, vomiting, and weight loss. Researchers will measure blood levels of a hormone called GDF-15 before and during treatment to see if changes in GDF-15 are linked to these side effects. If a link is found, it could help doctors identify patients at risk and manage side effects better in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors predict which breast cancer patients will have severe nausea or vomiting from T-DXd, allowing for better supportive care.
What could go wrong
This is an observational study, not a treatment trial. It only looks for a link between GDF-15 and side effects, so it won't directly improve outcomes. The results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Lake Macquarie Private Hospital
Newcastle, New South Wales, 2290, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Okayama University Hospital
Okayama, 700-8558, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact